Weekly Top News – Psoriasis – July 15, 2019

July 15, 2019

Humira (adalimumab) / Eisai, AbbVie; Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Comparing patient populations of the risankizumabphase III clinical trial programme to the U.K.general population: results from a British Association of Dermatologists Biologics and Immunomodulators Register analysis (BAD 2019) – Jul 11, 2019 – Abstract #P069; “The BADBIR cohort included 5657 patients aged ≥ 18 years, enrolled during 2007 to September 2017, receiving adalimumab for the first time, and from the U.K. and Republic of Ireland. AbbVie participated in the interpretation of data and review and approval of the publication. No authors were paid for writing this publication.”


mirikizumab (LY3074828) / Eli Lilly
Efficacy and safety of mirikizumab ( LY 3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study (BAD 2019) – Jul 11, 2019 – Abstract #88; No abstract available.


Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
NICE recommends funding for psoriasis and type 1 diabetes drugs (pharmaphorum) – Jul 12, 2019 – “Patients in England and Wales should soon be able to access AbbVie’s psoriasis drug Skyrizi after NICE recommended regular NHS funding….NICE reviewed Skyrizi (risankizumab) and made its recommendation meaning that NHS commissioners are committed to funding within 30 days of final guidance due at the end of August.”


Stelara (ustekinumab) / J&J
Retinal toxoplasmosis in psoriasis treated with ustekinumab: a case study (BAD 2019) – Jul 11, 2019 – Abstract #BI29; Pres time: Jul 2, 2019; 08:45 AM – 12:15 PM; Location: Hall 1B; “This has not yet been reported in the literature, and leads to the devastating outcome of permanent loss of vision, despite complete treatment with pyrimethamine, azithromycin, folinic acid and topical therapies. In conclusion, changing our practice depends on ongoing close surveillance of the side-effect profile of this drug to establish the risk better. Without awareness that presentations such as toxoplasma retinitis may be related to therapies such as ustekinumab, there may be under-reporting of these to the Medicines and Healthcare products Regulatory Agency, which will limit our ability to provide any evidence-based guidance.”


Stelara (ustekinumab) / J&J; Humira (adalimumab) / Eisai, AbbVie
Phenotypic switch from psoriasis to eczema onanti-interleukin-17 therapy: a case series (BAD 2019) – Jul 11, 2019 – Abstract #P038; “A woman in her late 20s presented with severe psoriasis vulgaris, who had failed to respond adequately to phototherapy, methotrexate, adalimumab and ustekinumab. We hypothesize that inhibition of the axis by secukinumab may be responsible for a shift towards the opposing Th2 cell axis, subsequent barrier disruption and eczema development. Ongoing postmarketing pharmacovigilance is important and further investigation is required to establish a causal link and understand the pathogenesis.”


Stelara (ustekinumab) / J&J; BMS-986165 / BMS
Efficacy and Safety of BMS-986165 Compared with Placebo in Subjects with Active Psoriatic Arthritis (PsA) A BMS-986165 placebóhoz viszonyított hatásossága és biztonságossága aktív artritisz pszoriatikában (PsA) szenvedő betegeknél (clinicaltrialsregister.eu) – Jul 9, 2019 – P2; N=180; Ongoing; Sponsor: Bristol-Myers Squibb International Corporation


Otezla (apremilast) / Celgene
Otezla patent expiry: Between 2023-2034 and 2023 for drug substance patent (Guggenheim) – Jul 9, 2019 – A subscription to Thomson ONE is required to gain full access to report 67532791; Page no: 2; REPORT TITLE: “Bristol-Myers Squibb Co. – BMY – They’re not gonna give Otezla away…but need to sell adds uncertainty & impacts timing”; AUTHOR: Fernandez, Seamus, et al; DATE: 06/25/2019

No Comments

Post a Comment